The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme: Clinical article

Journal of Neurosurgery

Volumn 110, Issue 1, 2009, Pages 147-155

  Sie, Mariska ^a   Wagemakers, Michiel ^b   Molema, Grietje ^b   Mooij, Jan Jakob A ^b   De Bont, Eveline S J M ^a   Den Dunnen, Wilfred F A ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Angiopoietin 1 angiopoietin 2 balance; Microvessel density; Primary glioblastoma multiforme; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BIOLOGICAL MARKER; CASPASE 3; CD34 ANTIBODY; MESSENGER RNA; RNA DIRECTED DNA POLYMERASE; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; CD34 ANTIGEN; KI 67 ANTIGEN; RNA; TUMOR MARKER;

ADULT; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MORPHOMETRICS; MULTIVARIATE ANALYSIS; NEUROSURGERY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR CELL; TUMOR NECROSIS; AGED; BIOSYNTHESIS; BRAIN TUMOR; DRUG EFFECT; GENETICS; KARNOFSKY PERFORMANCE STATUS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTIGENS, CD34; APOPTOSIS; BRAIN NEOPLASMS; CASPASE 3; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; KI-67 ANTIGEN; MALE; NEUROSURGICAL PROCEDURES; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60749127594     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2008.6.17612     Document Type: Article

References (40)

1. Ahmad SA, Liu W, Jung YD, Fan F, Wilson M, Reinmuth N, et al: The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 61:1255-1259, 2001 (Pubitemid 34292536)
2. Bach F, Uddin FJ, Burke D: Angiopoietins in malignancy. Eur J Surg Oncol 33:7-15, 2007 (Pubitemid 46156618)
3. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (3 Suppl):4-10, 2005
4. Currie MJ, Hanrahan V, Gunningham SP, Morrin HR, Frampton C, Han C, et al: Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. J Clin Pathol 57:829-834, 2004 (Pubitemid 39061431)
5. DeAngelis LM: Brain tumors. N Engl J Med 344:114-123, 2001
6. Debinski W, Slagle-Webb B, Achen MG, Stacker SA, Tulchinsky E, Gillespie GY, et al: VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol Med 7:598-608, 2001 (Pubitemid 34175288)
7. Dvorak HF: Angiogenesis: update 2005. J Thromb Haemost 3:1835-1842, 2005
8. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380, 2002
9. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG: Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388-1393, 2000 (Pubitemid 30152012)
10. Eklund L, Olsen BR: Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 312:630-641, 2006 (Pubitemid 43290339)
11. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M: Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 61:2145-2153, 2001 (Pubitemid 32692040)
12. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18:4-25, 1997 (Pubitemid 27076453)
13. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award lecture. Cancer Res 46:467-473, 1986
14. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
15. Gollmer JC, Ladoux A, Gioanni J, Paquis P, Dubreuil A, Chatel M, et al: Expression of vascular endothelial growth factorb in human astrocytoma. Neuro Oncol 2:80-86, 2000
16. Grau SJ, Trillsch F, Herms J, Thon N, Nelson PJ, Tonn JC, et al: Expression of VEGFR3 in glioma endothelium correlates with tumor grade. J Neurooncol 82:141-150, 2007 (Pubitemid 46431856)
17. Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94:883-893, 2002
18. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549-580, 2004 (Pubitemid 39658463)
19. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998, 1999 (Pubitemid 29309448)
20. Holash J, Wiegand SJ, Yancopoulos GD: New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356-5362, 1999 (Pubitemid 29462372)
21. Hu B, Guo P, Fang Q, Tao HQ, Wang D, Nagane M, et al: Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A 100:8904-8909, 2003 (Pubitemid 36899196)
22. Jain RK: Molecular regulation of vessel maturation. Nat Med 9:685-693, 2003
23. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
24. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622, 2007
25. Jenny B, Harrison JA, Baetens D, Tille JC, Burkhardt K, Mottaz H, et al: Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol 209:34-43, 2006
26. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG: Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 70:229-243, 2004 (Pubitemid 39545734)
27. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, et al: Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61:6248-6254, 2001 (Pubitemid 32762564)
28. Kuijlen JM, Mooij JJ, Platteel I, Hoving EW, van der Graaf WT, Span MM, et al: TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 78:161-171, 2006 (Pubitemid 44339684)
29. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al: The 2007 WHO classification of tumours of the central nervous system. Lyon. Acta Neuropathol 114:97-109, 2007
30. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60, 1997 (Pubitemid 27450643)
31. Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol 109:93-108, 2005 (Pubitemid 40287792)
32. Silvestre JS, Tamarat R, Ebrahimian TG, Le-Roux A, Clergue M, Emmanuel F, et al: Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 93:114-123, 2003 (Pubitemid 36919698)
33. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158:419-429, 2001 (Pubitemid 32158605)
34. Stratmann A, Risau W, Plate KH: Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459-1466, 1998 (Pubitemid 28509902)
35. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
36. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180, 1996 (Pubitemid 27010101)
37. Tait CR, Jones PF: Angiopoietins in tumours: the angiogenic switch. J Pathol 204:1-10, 2004
38. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, et al: Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38:1564-1579, 2002
39. Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, et al: In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159:391-400, 1999
40. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835, 1999